IDNA:NYE-iShares Genomics Immunology and Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 23.764

Change

-0.54 (-2.22)%

Market Cap

USD 0.14B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

ETFs Containing IDNA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.28% 19% F 52% F
Dividend Return 0.48% 53% F 10% F
Total Return 3.76% 24% F 43% F
Trailing 12 Months  
Capital Gain 5.43% 33% F 51% F
Dividend Return 1.25% 72% C 17% F
Total Return 6.68% 33% F 42% F
Trailing 5 Years  
Capital Gain -11.90% 5% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.90% 5% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -0.42% 14% F 36% F
Dividend Return 0.04% 14% F 28% F
Total Return 0.46% 53% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 37.14% 5% F 26% F
Risk Adjusted Return 0.10% 14% F 27% F
Market Capitalization 0.14B 60% D- 31% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.